Research Analysts Set Expectations for CANF FY2026 Earnings

Can-Fite BioPharma Ltd. (NYSE:CANF) – Analysts at HC Wainwright issued their FY2026 EPS estimates for Can-Fite BioPharma in a report released on Tuesday, November 4th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of $0.00 per share for the year. HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.00 EPS.

Separately, D. Boral Capital reiterated a “buy” rating and set a $11.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, September 16th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $6.75.

Can-Fite BioPharma Stock Performance

Can-Fite BioPharma stock opened at $0.42 on Thursday. The firm has a market cap of $1.47 million, a price-to-earnings ratio of -0.23 and a beta of 1.01. Can-Fite BioPharma has a 1 year low of $0.41 and a 1 year high of $2.38. The firm’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $0.83.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers grew its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,268 shares of the company’s stock after acquiring an additional 11,388 shares during the period. Rhumbline Advisers owned 1.08% of Can-Fite BioPharma worth $57,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.